FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.
What happened
In August 2025, FDA reviewed Tuyo Health’s website at https://www.tuyohealth.com and found it offering compounded semaglutide and tirzepatide. FDA said the site claimed these products have the “same active” ingredient as FDA-approved brand-name drugs such as Wegovy, Ozempic, Zepbound, and Mounjaro. FDA said those claims are false or misleading because compounded drugs are not FDA-approved.
What FDA found
The website claimed compounded semaglutide has the same active ingredient as Wegovy and Ozempic, which FDA says is false or misleading because compounded drugs are not FDA-approved.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claimed compounded tirzepatide has the same active ingredient as Zepbound and Mounjaro, which FDA says is false or misleading because compounded drugs are not FDA-approved.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website’s advertising or promotion of compounded drugs was false or misleading.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Tuyo Health introduced or delivered misbranded drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce and delivering or offering to deliver them is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Tuyo Health to take immediate action, including stopping the misleading claims, and to send a written response to CDER’s Office of Compounding Quality and Compliance within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and their telehealth partners
- marketers and websites promoting compounded drug products
This is a summary. Read the original letter on fda.gov.